PuraMed BioScience

Where is PuraMed BioScience’s corporate headquarters?
Where is the company incorporated?
When did PuraMed BioScience become a publicly-traded corporation?
When is PuraMed BioScience fiscal year end?
Where is PuraMed BioScience stock traded?
When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
Do PuraMed BioScience products require FDA approval?
How many products does PuraMed BioScience have in progress?
Does PuraMed BioScience currently pay dividends?
Who is the PuraMed BioScience transfer agent?
Who should I contact with questions about PuraMed BioScience stock?
How do I transfer stock, change the address on my shareholder account or replace a lost stock certificate?
Does PuraMed BioScience have a direct stock purchase plan?
How big is the non-prescription market for migraines, insomnia and tension headaches?
When do you anticipate generating revenue?
When do you expect to launch first product in retail or commercial environment?
What are PuraMed BioScience’s plans regarding conducting human clinical trials?
What are the advantages of sublingual (under the tongue) delivery?
Does PuraMed BioScience manufacture its own products?

Where is PuraMed BioScience’s corporate headquarters?
PuraMed BioScience is headquartered in Schofield, Wisconsin, which is a suburb of Wausau, Wisconsin. The city is located in the central part of the state.

Where is the company incorporated?
PuraMed BioScience is a Minnesota-based corporation.

When did PuraMed BioScience become a publicly-traded corporation?
PuraMed BioScience officially went public in October 2007 when our Form10-SB was approved by the SEC. In May 2008, PuraMed BioScience was granted a trading symbol (OTCBB:PMBS) and we started trading.the central part of the state.

When is PuraMed BioScience fiscal year end?
PuraMed the central part of the state. BioScience’s fiscal year ends on June 30th.

Where is PuraMed BioScience stock traded?
PuraMed BioScience stock is traded on the OTC Bulletin Board using trading symbol the central part of the state. (OTCBB:PPMBS).

When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?
PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.

Do PuraMed BioScience products require FDA approval?
Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.

How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.

Does PuraMed BioScience currently pay dividends?
The Company did not declare or pay any cash dividends on its common stock during the last two fiscal years ended June 30, 2008 and 2009; nor does the company expect to pay cash dividends for the foreseeable future.

Who is the PuraMed BioScience transfer agent?
PuraMed BioScience’s transfer agent is Interwest Transfer Company, Inc., located in Salt Lake City, Utah. http://www.interwesttc.com/

Who should I contact with questions about PuraMed BioScience stock?
Questions regarding the PuraMed BioScience stock can be directed to Russell Mitchell, CEO; or James Higgins, CFO; via email; or directly via phone at 715.359.6373.

How do I transfer stock, change the address on my shareholder account or replace a lost stock certificate?
a. Issues regarding the PuraMed BioScience stock certificates should be addressed by the company before being sent to our transfer agent. Questions regarding the PuraMed BioScience stock can be directed to Russell Mitchell, CEO; or James Higgins, CFO; via email; or directly via phone at 715.359.6373.

Does PuraMed BioScience have a direct stock purchase plan?
Yes. PuraMed will be raising needed capital via private placement of their common stock over the next six months. Interested parties can contact the company directly at 715.359.6373 to make an inquiry.

How big is the non-prescription market for migraines, insomnia and tension headaches?
Currently, the non-prescription market for headache pain and sleep is approximately $2.68 billion without Walmart and approximately $3.2 with Walmart.

When do you anticipate generating revenue?
PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.

When do you expect to launch first product in retail or commercial environment?
PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.

What are PuraMed BioScience’s plans regarding conducting human clinical trials?
Even though PuraMed is not required to conduct clinical trials prior to marketing its products, it is committed to utilizing clinical research in order to improve its product mix as well as provide third-party validation to its current products. Published scientific evidence provides greater opportunities to promote PuraMed products within the medical community, consumer advocates, the mainstream press, the retail community and other venues.

What are the advantages of sublingual (under the tongue) delivery?
a. The Lipigesic™ M, Lipigesic™ PM and Lipigesic™ H are non-prescription, liquid medications that are formulated for absorption under-the tongue. This type of delivery is known as “sublingual.” Unlike the majority of pills and medications absorbed through the stomach, PuraMed products are placed and absorbed directly under the tongue. Advantages of the sublingual dispensing of drugs and medications include faster acting absorption for quick relief, improved efficacy, less stomach upset, and fewer side effects. The use of sublingual delivery provides fast relief for whatever ailment or condition is being treated.

b. The second advantage of sublingual absorption is that dosing the drug under your tongue bypasses the “first pass effect”. The “first pass effect” refers to the neutralizing effect the stomach and liver have on medicines that are dosed orally. Larger doses of drugs are required for orally ingested pills and liquids because the stomach and liver will breakdown a significant percentage of the drug before it can be absorbed into the bloodstream. Since sublingual absorption bypasses the stomach and liver, it maintains the effectiveness of a smaller dose of the drug.

Does PuraMed BioScience manufacture its own products?
Production and packaging of PuraMed BioScience products will be outsourced to various contract manufacturers based on prior substantial business and contractual experiences and recommendations by PuraMed’s management team. Due to the business and contacts developed by PuraMed’s management over the past years with leading contract manufacturers, PuraMed is convinced it can obtain professional and timely production, packaging and delivery of all PuraMed products. PuraMed believes this structure will significantly reduce the developmental- stage costs and developmental time related to launching each PuraMed product commercially.